Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT03030066
PHASE1
Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas
Sponsor: Daiichi Sankyo
View on ClinicalTrials.gov
Summary
This is a study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of DS-1001b in patients with gliomas that harbor IDH1-R132 mutations.
Official title: A Phase 1 Study of DS-1001b in Patients With IDH1 Mutated Gliomas
Key Details
Gender
All
Age Range
20 Years - Any
Study Type
INTERVENTIONAL
Enrollment
47
Start Date
2017-01-19
Completion Date
2026-08-31
Last Updated
2026-02-04
Healthy Volunteers
No
Conditions
Interventions
DRUG
DS-1001b
Generic not assigned
Locations (1)
National Cancer Center Hospital
Tokyo, Japan